Traws Pharma

TRAW

Market cap $13.1M

Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript

Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity,

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID ® -ineligible patients, representing a significant population with no effective treatment options

IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile

SAN DIEGO , Oct. 30, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC) services collaboration supporting the clinical development of ratutrelvir, a promising oral antiviral treatment for COVID-19. The announcement follows recent progress by Traws Pharma, Inc. (NASDAQ: TRAW), which dosed the first patient in Phase 2 studies of ratutrelvir in October 2025, with top-line data expected by year-end 2025.

DOVER, Del. , Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.

Non-inferiority trial versus PAXLOVID ® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment

Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID ®

Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - Interim CEO, Secretary & Director Robert R.